Literature DB >> 26551691

TSPO is a REDOX regulator of cell mitophagy.

Jemma Gatliff1, Michelangelo Campanella2.   

Abstract

The mitochondrial 18-kDa translocator protein (TSPO) was originally discovered as a peripheral binding site of benzodiazepines to be later described as a core element of cholesterol trafficking between cytosol and mitochondria from which the current nomenclature originated. The high affinity it exhibits with chemicals (i.e. PK11195) has generated interest in the development of mitochondrial based TSPO-binding drugs for in vitro and in vivo analysis. Increased TSPO expression is observed in numerous pathologies such as cancer and inflammatory conditions of the central nervous system (CNS) that have been successfully exploited via protocols of positron emission tomography (PET) imaging. We endeavoured to dissect the molecular role of TSPO in mitochondrial cell biology and discovered a functional link with quality control mechanisms operated by selective autophagy. This review focuses on the current understanding of this pathway and focuses on the interplay with reactive oxygen species (ROS) and the voltage-dependent anion channel (VDAC), to which TSPO binds, in the regulation of cell mitophagy and hence homoeostasis of the mitochondrial network as a whole.
© 2015 Authors; published by Portland Press Limited.

Entities:  

Keywords:  autophagy; mitochondria; translocator protein (TSPO); voltage-dependent anion channel 1 (VDAC1) and reactive oxygen species (ROS)

Mesh:

Substances:

Year:  2015        PMID: 26551691     DOI: 10.1042/BST20150037

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  23 in total

Review 1.  Exploring mitochondrial cholesterol signalling for therapeutic intervention in neurological conditions.

Authors:  Radha Desai; Michelangelo Campanella
Journal:  Br J Pharmacol       Date:  2019-08-09       Impact factor: 8.739

2.  Decreased Mitochondrial Dynamics Is Associated with Insulin Resistance, Metabolic Rate, and Fitness in African Americans.

Authors:  John J Dubé; Michael L Collyer; Sara Trant; Frederico G S Toledo; Bret H Goodpaster; Erin E Kershaw; James P DeLany
Journal:  J Clin Endocrinol Metab       Date:  2020-04-01       Impact factor: 5.958

Review 3.  VDAC2 as a novel target for heart failure: Ca2+ at the sarcomere, mitochondria and SR.

Authors:  Paul Rosenberg
Journal:  Cell Calcium       Date:  2022-03-28       Impact factor: 4.690

4.  Novel application of complementary imaging techniques to examine in vivo glucose metabolism in the kidney.

Authors:  Takashi Hato; Allon N Friedman; Henry Mang; Zoya Plotkin; Shataakshi Dube; Gary D Hutchins; Paul R Territo; Brian P McCarthy; Amanda A Riley; Kumar Pichumani; Craig R Malloy; Robert A Harris; Pierre C Dagher; Timothy A Sutton
Journal:  Am J Physiol Renal Physiol       Date:  2016-01-13

Review 5.  Insight into the Structural Features of TSPO: Implications for Drug Development.

Authors:  Jean-Jacques Lacapere; Luminita Duma; Stephanie Finet; Michael Kassiou; Vassilios Papadopoulos
Journal:  Trends Pharmacol Sci       Date:  2019-12-18       Impact factor: 14.819

6.  Antipsychotics, versatility in action.

Authors:  Sidharth Mahapatra; Tiago Reis Marques
Journal:  Proc Natl Acad Sci U S A       Date:  2021-07-13       Impact factor: 11.205

7.  Evaluation of [18F]F-DPA as a target for TSPO in head and neck cancer under normal conditions and after radiotherapy.

Authors:  Sanni Tuominen; Thomas Keller; Nataliia Petruk; Francisco López-Picón; Dominik Eichin; Eliisa Löyttyniemi; Alejandra Verhassel; Johan Rajander; Jouko Sandholm; Johanna Tuomela; Tove J Grönroos
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-12-19       Impact factor: 9.236

Review 8.  TSPO protein binding partners in bacteria, animals, and plants.

Authors:  Carrie Hiser; Beronda L Montgomery; Shelagh Ferguson-Miller
Journal:  J Bioenerg Biomembr       Date:  2021-06-30       Impact factor: 2.945

9.  High-throughput screening of clinically approved drugs that prime polyethylenimine transfection reveals modulation of mitochondria dysfunction response improves gene transfer efficiencies.

Authors:  Albert Nguyen; Jared Beyersdorf; Jean-Jack Riethoven; Angela K Pannier
Journal:  Bioeng Transl Med       Date:  2016-07-21

10.  The mitochondria-targeted antioxidant MitoQ ameliorated tubular injury mediated by mitophagy in diabetic kidney disease via Nrf2/PINK1.

Authors:  Li Xiao; Xiaoxuan Xu; Fan Zhang; Ming Wang; Yan Xu; Dan Tang; Jiahui Wang; Yan Qin; Yu Liu; Chengyuan Tang; Liyu He; Anna Greka; Zhiguang Zhou; Fuyou Liu; Zheng Dong; Lin Sun
Journal:  Redox Biol       Date:  2016-12-21       Impact factor: 11.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.